Abacus Medicine completed the acquisition of Swiss Cardio Technologies.

Abacus Medicine, a Copenhagen-based pharmaceuticals company, completed the acquisition of Swiss Cardio Technologies, a Swiss medical technology company. Financial terms were not disclosed. “Swiss Cardio Technologies exemplifies excellence in healthcare innovation. The opportunities for our two organisations are significant, and I look forward to exploring them together. This acquisition of our first pharmaceutical asset is a strategic addition to the Group’s business model and our plans for continued profitable growth. It marks the beginning of a new chapter,” Flemming Wagner, Abacus Medicine CEO.